Trivium Point Advisory LLC Purchases 10,440 Shares of Medtronic PLC $MDT

Trivium Point Advisory LLC increased its holdings in shares of Medtronic PLC (NYSE:MDT) by 20.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 60,877 shares of the medical technology company’s stock after acquiring an additional 10,440 shares during the quarter. Trivium Point Advisory LLC’s holdings in Medtronic were worth $5,848,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Corundum Trust Company INC acquired a new stake in Medtronic in the third quarter valued at $27,000. Lodestone Wealth Management LLC bought a new stake in Medtronic in the fourth quarter valued at approximately $27,000. Board of the Pension Protection Fund bought a new position in Medtronic during the 4th quarter worth approximately $29,000. GoalVest Advisory LLC acquired a new position in shares of Medtronic in the 4th quarter worth approximately $29,000. Finally, Valley Wealth Managers Inc. bought a new stake in shares of Medtronic in the 3rd quarter valued at $29,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Stock Performance

Shares of MDT opened at $85.66 on Friday. The stock has a 50 day moving average of $91.85 and a 200 day moving average of $95.75. The company has a market capitalization of $109.98 billion, a price-to-earnings ratio of 23.86, a PEG ratio of 2.26 and a beta of 0.75. Medtronic PLC has a 12 month low of $79.93 and a 12 month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same quarter last year, the business posted $1.38 EPS. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be given a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is currently 79.11%.

Wall Street Analyst Weigh In

MDT has been the topic of several recent analyst reports. Citigroup dropped their target price on shares of Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Daiwa Securities Group reduced their price objective on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, February 27th. UBS Group restated a “neutral” rating and issued a $104.00 price target on shares of Medtronic in a report on Wednesday, February 4th. Stifel Nicolaus cut their price objective on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research report on Monday, April 6th. Finally, Truist Financial dropped their price target on Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a research note on Wednesday. Sixteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.25.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of Medtronic stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).